Berbamine induces fas-mediated apoptosis in human hepatocellular carcinoma hepG2 cells and inhibits its tumor growth in nude mice

Journal of Asian Natural Products Research

Volumn 11, Issue 3, 2009, Pages 219-228

  Wang, Guan Yu ^a   Lv, Qing Hua ^b,c   Dong, Qi ^b,c   Xu, Rong Zhen ^b,c   Dong, Qing Hua ^b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Berbamine; Caspase; Fas; Hepatocellular carcinoma; P53

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BERBAMINE; CASPASE 3; CASPASE 8; CASPASE 9; FAS ANTIGEN; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN P53; ANTINEOPLASTIC AGENT; BENZYLISOQUINOLINE DERIVATIVE; BERBERINE; PIBENZIMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CHINESE MEDICINE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; MEDICINAL PLANT; METABOLISM; NUDE MOUSE; TIME;

BERBERIS AMURENSIS; MUS; MUS MUSCULUS;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZYLISOQUINOLINES; BERBERINE; BISBENZIMIDAZOLE; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; PLANTS, MEDICINAL; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65649088963     PISSN: 10286020     EISSN: 14772213     Source Type: Journal    
DOI: 10.1080/10286020802675076     Document Type: Article

References (19)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani, Int. J. Cancer 94, 153 (2001).
2. A.J. Hall and C.P. Wild, Br. Med. J. 326, 994 (2003).
3. K. Yang, X. Zhao, P. Xiao, and G. Liu, Yao Hsueh Tung Pao 17, 21 (1982).
4. C.Q. Xu, D.L. Dong, Z.M. Du, D.W. Chen, D.M. Gong, and B.F. Yang, Acta Pharm. Sin. 9, 691 (2004).
5. E. Kupeli, M. Kosar, E. Yasilada, K. Husnu, and C. Baser, Life Sci. 72, 645 (2002).
6. D. Wu, M.F. Lin, and X.Y. Zhao, Zhongguo Shi Yan Xue Ye Xue Za Zhi 13, 373 (2005).
7. R.Z. Xu, Q.H. Dong, Y. Yu, X. Zhao, X. Gan, D. Wu, Q. Lu, X. Xu, and X.F. Yu, Leuk. Res. 30, 17 (2006).
8. Q.H. Dong, S. Zheng, R.Z. Xu, Q.H. Lu, and L. He, Zhongguo Zhong Xi Yi Jie He Za Zhi 24, 820 (2004).
9. X.W. Zhu and W.Z. Sui, Zhong Xi Yi Jie He Za Zhi 6, 611 (1986).
10. V. Sharma, R. Tewari, U.H. Sk, C. Joseph, and E. Sen, Int. J. Cancer 123, 2204 (2008).
11. B.C. Barnhart, E.C. Alappat, and M.E. Peter, Immunology 15, 185 (2003).
12. H. Li, H. Zhu, C.J. Xu, and J. Yuan, Cell 94, 491 (1998).
13. M.D. McKenzie, E.M. Carrington, T. Kaufmann, A. Strasser, D.C. Huang, T.W. Kay, J. Allison, and H.E. Thomas, Diabetes 57, 1284 (2008).
14. J.K. Rho, Y.J. Choi, B.Y. Ryoo, I.I. Na, S.H. Yang, C.H. Kim, and J.C. Lee, Cancer Res. 67, 1163 (2007).
15. M. Muller, S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, M. Li-Weber, S.L. Friedman, P.R. Galle, W. Stremmel, M. Oren, and P.H. Krammer, J. Exp. Med. 188, 2033 (1998).
16. E. Kupeli, M. Kosar, E. Yasilada, K. Husnu, and C. Baser, Life Sci. 72, 645 (2002).
17. C. Luo, X. Lin, W.K. Li, F. Pu, L.W. Wang, S. Xie, and P. Xiao, J. Ethnopharmacol. 59, 211 (1998).
18. X. Liu and Z.R. Zhou, J. Chin. Med. Univ. 25, 229 (1996).
19. M.Z. Ge, X. Liu, and Y. Zhang, Immunol. J. 14, 238 (1998).